Italia markets closed

CRSP Jan 2025 32.500 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,95000,0000 (0,00%)
In data: 01:23PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,9500
Aperto0,9500
Denaro0,9000
Domanda1,2500
Prezzo d'esercizio32,50
Scadenza2025-01-17
Min-Max giorno0,9500 - 0,9500
Contratto - Min-MaxN/D
Volume10
Open Interest41
  • GlobeNewswire

    CRISPR Therapeutics Proposes New Appointment to the Board of Directors

    ZUG, Switzerland and BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Sandy Mahatme, LL.M. to its Board of Directors at the Company’s next annual general meeting to be held in 2024. “I am honored to welcome Sandy to our Board during an important time in CRISPR Therapeutics’ continued evolution,” said Samarth Kulkarni, Ph.D., C

  • GlobeNewswire

    CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

    ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023. Title: Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CAR T cell

  • GlobeNewswire

    CRISPR Therapeutics Announces Leadership Transition

    -CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023--Samarth Kulkarni, Ph.D., to succeed Dr. Novak as Chairman and will continue serving as CEO of the Company- ZUG, Switzerland and BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Rodger Novak, M.D., President and Chairman